doi:10.1002/chem.202003788
Cardiovascular Considerations Some studies have noted cardiovascular-related observations in participants receiving aod 9604 peptide therapy : Heart rate variations in sensitive individuals Blood pressure fluctuations during initial administration periods Palpitations reported by less than 1% of research subjects These cardiovascular effects appear to be dose-dependent and more common when aod 9604 peptide dosage exceeds established research guidelines
Inert Gas Sealing: After removing the needed amount, reseal containers under dry, inert gas (e.g., nitrogen or argon) to prevent oxidation of remaining peptides
Yen, Head of the Laboratory of Hormonal Regulation at Duke-NUS' Cardiovascular & Metabolic Disorders Programme, and senior author of the study, said, "The potential for using vitamin B12 and folate, which have high safety profiles and are designated as dietary supplements by the US Food and Drug Administration, as first-line therapies for the prevention and treatment of NASH could result in tremendous cost savings and reduce the health burden from NASH in both developed and developing countries." Currently, the only treatment for patients with end-stage liver disease is to receive a transplant
What the animal studies cannot tell us includes optimal human dosing, population-specific responses (elderly, children, pregnancy), long-term safety in humans, rare side effects that require large sample sizes to detect, and interactions with medications or medical conditions
